Illumina Launches Distributed WGS MRD Kit with 10 ppm Sensitivity, 99.5% Specificity
ILMN•Illumina introduced a distributed whole-genome sequencing kit for MRD research with 10 ppm sensitivity and 99.5% specificity via DRAGEN, delivering results in five days. Early-access trials with Mayo Clinic demonstrated high concordance, and full global rollout is planned next year alongside NovaSeq X portfolio expansions.
1. Product Introduction
Illumina has unveiled its first distributed whole-genome sequencing solution for molecular residual disease research, marking the launch of a new WGS oncology portfolio. The kit supports both solid tumor fingerprinting and blood-based ctDNA MRD profiling, extending the reach of precision oncology into more research labs.
2. Performance and Workflow
The end-to-end workflow can be completed in as fast as five days and is optimized for analytical sensitivity down to 10 ppm. Coupled with DRAGEN MRD analysis, the solution delivers 99.5% specificity to distinguish true tumor signals from background noise.
3. Early Access and Validation
The MRD solution is now in early access with select partners, including Mayo Clinic, where pilot trials showed high concordance with existing clinical and imaging data. Illumina and Bristol Myers Squibb will present validation results at the upcoming ASCO Annual Meeting.
4. Future Roadmap and Launch
Built on NovaSeq X advancements such as 35 billion reads output and Q70 quality, Illumina is developing duplex-read workflows targeting single-digit ppm sensitivity. The solution will become globally available next year as part of the broader NovaSeq X oncology portfolio enhancements.
